Rashmi Kanagal-Shamanna, MD, Discusses Optical Genome Mapping
By Leah Sherwood, Rashmi Kanagal-Shamanna, MD - Last Updated: February 27, 2023Rashmi Kanagal-Shamanna, MD, of the MD Anderson Cancer Center, discusses the optical genome mapping platform and the clinical implications the technology will have for patients with acute myeloid leukemia and myelodysplastic syndromes.
Advertisement
Advertisement
Related Posts
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
A systemic review found that 21 of 90 randomized controlled trials for AML reported on patients' race and ethnicity.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.